Aminoadipate aminotransferase (AADAT) consists of a mitochondrial cleavage signal and a pyridoxal-phosphate binding site. The protein is majorly expressed in liver and brain. The gene is located on human chromosome 4q33.
Synonyms: Anti-Aminoadipate aminotransferase; Anti-KAT2; Anti-KATII
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Aminoadipate aminotransferase (AADAT) catalyses the conversion of a-aminoadipate to a-ketoadipate, which is an intermediate step in lysine degradation. Isoforms of AADAT regulate lysine and tryptophan metabolism. It also catalyses the transamination of kynurenine to KYNA (kynurenic acid). The protein is considered as a therapeutic target for schizophrenia and cognitive impairment.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC